Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 282

1.

Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.

Christoph F, Weikert S, Wolff I, Schostak M, Tabiti K, Müller M, Miller K, Schrader M.

Cancer Lett. 2007 Jan 8;245(1-2):121-6. Epub 2006 Feb 13.

PMID:
16473461
2.

Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.

Christoph F, Müller M, Schostak M, Soong R, Tabiti K, Miller K.

Urology. 2004 Jul;64(1):157-61.

PMID:
15245962
3.

Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.

Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkorn I.

Cancer. 1998 Jan 15;82(2):349-54.

PMID:
9445193
4.
5.

Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer.

Okegawa T, Kinjo M, Nutahara K, Higashihara E.

J Urol. 2004 Apr;171(4):1461-6.

PMID:
15017198
6.

Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas.

Pina-Cabral L, Santos L, Mesquita B, Amaro T, Magalhães S, Criado B.

Clin Transl Oncol. 2007 Nov;9(11):731-6.

PMID:
18055328
7.

Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.

Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB.

Anticancer Res. 2003 Jul-Aug;23(4):3327-31.

PMID:
12926071
8.
9.

Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.

Elsamman E, Fukumori T, Kasai T, Nakatsuji H, Nishitani MA, Toida K, Ali N, Kanayama HO.

BJU Int. 2006 Jun;97(6):1202-7.

10.
11.

Urinary cytokeratin 20 as a marker for transitional cell carcinoma.

Rotem D, Cassel A, Lindenfeld N, Mecz Y, Sova Y, Resnick M, Stein A.

Eur Urol. 2000 May;37(5):601-4.

PMID:
10765100
12.

Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.

Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H.

Oncol Rep. 2009 Jun;21(6):1495-504.

PMID:
19424629
13.

Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor.

Okegawa T, Kinjo M, Horie S, Nutahara K, Higashihara E.

Urology. 2003 Jul;62(1):182-6.

PMID:
12837463
15.

Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.

Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J, Manor E.

Urology. 2004 Feb;63(2):398-401.

PMID:
14972510
16.

Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.

Tsui KH, Cheng AJ, Chang Pe, Pan TL, Yung BY.

Urology. 2004 Oct;64(4):839-44.

PMID:
15491744
17.

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.

Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO.

Clin Cancer Res. 2004 May 15;10(10):3410-21.

18.

Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.

Eissa S, Zohny SF, Swellam M, Mahmoud MH, El-Zayat TM, Salem AM.

Clin Biochem. 2008 Nov;41(16-17):1335-41. doi: 10.1016/j.clinbiochem.2008.08.085. Epub 2008 Sep 9.

PMID:
18804101
19.

Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.

Retz M, Lehmann J, Amann E, Wullich B, Röder C, Stöckle M.

J Urol. 2003 Jan;169(1):86-9.

PMID:
12478110
20.

Supplemental Content

Support Center